دورية أكاديمية
أعرض في EDS

Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.

التفاصيل البيبلوغرافية
العنوان: Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.
المؤلفون: Jongkees MJ; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases., Tan NH; Department of Hospital Pharmacy., Geers D; Department of Viroscience., de Vries RD; Department of Viroscience., GeurtsvanKessel CH; Department of Viroscience., Hensley KS; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases., Sablerolles RSG; Department of Hospital Pharmacy., Bogers S; Department of Viroscience., Gommers L; Department of Viroscience., Blakaj B; Department of Medical Oncology., Miranda Afonso P; Department of Biostatistics and Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, the Netherlands., Hansen BE; Department of Biostatistics and Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, the Netherlands.; Institute of Health Policy, Management and Evaluation, University of Toronto.; Toronto Centre for Liver Disease, Toronto General Hospital University Health Network, Toronto, Canada., Rijnders BJA; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases., Brinkman K; Department of Internal Medicine and Infectious Diseases, OLVG Hospital, Amsterdam., van der Kuy PHM; Department of Hospital Pharmacy., Roukens AHE; Department of Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands., Rokx C; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases.
المصدر: AIDS (London, England) [AIDS] 2024 Jul 15; Vol. 38 (9), pp. 1355-1365. Date of Electronic Publication: 2024 May 28.
نوع المنشور: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : London, England : Lippincott Williams & Wilkins
Original Publication: London : Gower Academic Journals, c1987-
مواضيع طبية MeSH: Immunization, Secondary* , HIV Infections*/immunology , COVID-19*/prevention & control , COVID-19*/immunology , COVID-19 Vaccines*/immunology , COVID-19 Vaccines*/administration & dosage , Immunogenicity, Vaccine* , Antibodies, Viral*/blood , Antibodies, Viral*/immunology , BNT162 Vaccine*/immunology , BNT162 Vaccine*/administration & dosage , SARS-CoV-2*/immunology, Humans ; Male ; Middle Aged ; Female ; Prospective Studies ; Netherlands ; Adult ; 2019-nCoV Vaccine mRNA-1273/immunology ; 2019-nCoV Vaccine mRNA-1273/administration & dosage ; Cytokines/immunology ; Aged
مستخلص: Objective: We evaluated the immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV (PWH).
Design: Prospective observational cohort study.
Methods: PWH aged ≥45 years received Wuhan-BA.1 mRNA-1273.214 and those <45 years Wuhan-BA.1 BNT162b2. Participants were propensity score-matched 1 : 2 to people without HIV (non-PWH) by age, primary vaccine platform (mRNA-based or vector-based), number of prior COVID-19 boosters and SARS-CoV-2 infections, and spike (S1)-specific antibodies on the day of booster administration. The primary endpoint was the geometric mean ratio (GMR) of ancestral S1-specific antibodies from day 0 to 28 in PWH compared to non-PWH. Secondary endpoints included humoral responses, T-cell responses and cytokine responses up to 180 days post-vaccination.
Results: Forty PWH received mRNA-1273.214 ( N  = 35) or BNT162b2 ( N  = 5) following mRNA-based ( N  = 29) or vector-based ( N  = 11) primary vaccination. PWH were predominantly male (87% vs. 26% of non-PWH) and median 57 years [interquartile range (IQR) 53-59]. Their median CD4 + T-cell count was 775 (IQR 511-965) and the plasma HIV-RNA load was <50 copies/ml in 39/40. The GMR of S1-specific antibodies by 28 days post-vaccination was comparable between PWH [4.48, 95% confidence interval (CI) 3.24-6.19] and non-PWH (4.07, 95% CI 3.42-4.83). S1-specific antibody responses were comparable between PWH and non-PWH up to 180 days, and T-cell responses up to 90 days post-vaccination. Interferon-γ, interleukin (IL)-2, and IL-4 cytokine concentrations increased 28 days post-vaccination in PWH.
Conclusion: A bivalent BA.1 booster vaccine was immunogenic in well treated PWH, eliciting comparable humoral responses to non-PWH. However, T-cell responses waned faster after 90 days in PWH compared to non-PWH.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Int J Infect Dis. 2023 Sep;134:195-199. (PMID: 37343783)
PLoS Med. 2022 Oct 27;19(10):e1003979. (PMID: 36301821)
Front Med (Lausanne). 2023 Oct 09;10:1275843. (PMID: 37877024)
Epidemiol Infect. 2023 Sep 14;151:e176. (PMID: 37704371)
J Infect Dis. 2023 Mar 1;227(5):651-662. (PMID: 36402141)
Lancet. 2022 Mar 19;399(10330):1141-1153. (PMID: 35305740)
N Engl J Med. 2023 Jan 19;388(3):214-227. (PMID: 36652353)
Front Immunol. 2022 May 10;13:864838. (PMID: 35619709)
BMJ. 2022 Mar 9;376:e069761. (PMID: 35264324)
Clin Infect Dis. 2023 Nov 30;77(11):1511-1520. (PMID: 37392436)
JAMA Netw Open. 2022 Jun 1;5(6):e2215934. (PMID: 35671054)
N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
Sci Immunol. 2022 Mar 25;7(69):eabo2202. (PMID: 35113647)
Lancet Infect Dis. 2023 Aug;23(8):901-913. (PMID: 37088096)
Sci Rep. 2023 Jun 19;13(1):9893. (PMID: 37336939)
N Engl J Med. 2022 Oct 6;387(14):1279-1291. (PMID: 36112399)
Lancet Infect Dis. 2023 Jul;23(7):816-827. (PMID: 36913963)
Am J Epidemiol. 2010 Nov 1;172(9):1092-7. (PMID: 20802241)
AIDS. 2023 Jul 15;37(9):1345-1360. (PMID: 37070539)
NPJ Vaccines. 2023 May 17;8(1):70. (PMID: 37198189)
Int J Infect Dis. 2022 Nov;124:212-223. (PMID: 36241168)
Nat Commun. 2024 May 18;15(1):4224. (PMID: 38762522)
AIDS. 2023 Apr 1;37(5):F11-F18. (PMID: 36789806)
EClinicalMedicine. 2023 Jul 20;62:102102. (PMID: 37533414)
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Antibodies, Viral)
0 (BNT162 Vaccine)
EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
0 (Cytokines)
تواريخ الأحداث: Date Created: 20240524 Date Completed: 20240627 Latest Revision: 20240708
رمز التحديث: 20240708
مُعرف محوري في PubMed: PMC11216395
DOI: 10.1097/QAD.0000000000003933
PMID: 38788210
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5571
DOI:10.1097/QAD.0000000000003933